Medicare Advantage
Advanced Search
  
  
  
  
  
  
  
  
  
  
  
  
News & AnnouncementsPharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 4, 2021)5/4/2021Pharmaceutical Treatments of COVID-19 for Independence Medicare Advantage Members (Updated May 4, 2021)
News & AnnouncementsTelehealth Services for Medicare Advantage Members (updated May 7, 2021)5/7/2021Telehealth Services for Medicare Advantage Members (updated May 7, 2021)
News & AnnouncementsTelehealth Services for Medicare Advantage Members (Updated March 19, 2021)5/7/2021Telehealth Services for Medicare Advantage Members (Updated March 19, 2021)
News & AnnouncementsTelehealth Services for Medicare Advantage Members (Updated March 19, 2021)5/7/2021Telehealth Services for Medicare Advantage Members (Updated March 19, 2021)
News & AnnouncementsTelehealth Services for Medicare Advantage Members (Updated March 19, 2021)5/8/2021Telehealth Services for Medicare Advantage Members (Updated March 19, 2021)
News & AnnouncementsTelehealth Services for Medicare Advantage Members (updated May 13, 2021)5/13/2021Telehealth Services for Medicare Advantage Members (updated May 13, 2021)
News & AnnouncementsGround Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated May 20, 2021)5/20/2021Ground Ambulance Transport Services (Emergency and Nonemergency) for Medicare Advantage Members (Updated May 20, 2021)
NotificationsInebilizumab-cdon (Uplizna)MA08.126b5/11/2021 1:00 PM8/9/20215/11/2021Medical Necessity Criteria;General Description, Guidelines, or Informational UpdateInebilizumab-cdon (Uplizna)
New PoliciesMelphalan flufenamide (Pepaxto®)MA08.1355/10/20215/10/2021This is a New Policy.Melphalan flufenamide (Pepaxto®)
New PoliciesFilgrastim  (Neupogen ®) and related biosimilars, and Tbo-filgrastim (Granix ®)MA08.13012/31/2020 10:00 AM4/1/20215/13/2021This is a New Policy.5/13/2021Filgrastim  (Neupogen ®) and related biosimilars, and Tbo-filgrastim (Granix ®)
New PoliciesTeprotumumab (Tepezza™)MA08.1154/23/2021 10:00 AM5/24/20215/24/2021This is a New Policy.Teprotumumab (Tepezza™)
New Policiesevinacumab-dgnb (Evkeeza)MA08.1335/24/20215/24/2021This is a New Policy.evinacumab-dgnb (Evkeeza)
Updated PoliciesBotulinum Toxin AgentsMA08.017f5/3/20215/3/2021Medical Necessity Criteria;Medical CodingBotulinum Toxin Agents
Updated PoliciesContrast Agents Used in Conjunction with EchocardiographyMA09.004c4/2/2021 2:00 PM5/3/20215/3/2021General Description, Guidelines, or Informational UpdateContrast Agents Used in Conjunction with Echocardiography
Updated PoliciesDenosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)MA08.052i5/10/20215/10/2021Medical Necessity CriteriaDenosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)
Updated PoliciesFam-trastuzumab deruxtecan-nxki (Enhertu®)MA08.114b5/24/20215/24/2021Medical Necessity Criteria;Medical CodingFam-trastuzumab deruxtecan-nxki (Enhertu®)
Updated PoliciesLurbinectedin (Zepzelca)MA08.125b5/24/20215/24/2021Medical Necessity CriteriaLurbinectedin (Zepzelca)
Updated PoliciesIsatuximab-irfc (Sarclisa®)MA08.117b5/24/20215/24/2021Medical Necessity Criteria;General Description, Guidelines, or Informational UpdateIsatuximab-irfc (Sarclisa®)
Updated PoliciesFecal Microbiota Transplantation (FMT)MA07.006b5/31/20215/28/2021Medical Necessity Criteria;General Description, Guidelines, or Informational UpdateFecal Microbiota Transplantation (FMT)
Reissue Policiesbelantamab mafodotin-blmf (Blenrep) MA08.119b4/1/20215/5/20215/5/2021belantamab mafodotin-blmf (Blenrep)
Reissue Policiescrizanlizumab-tmca (Adakveo®)MA08.109a10/1/20205/5/20215/5/2021crizanlizumab-tmca (Adakveo®)
Reissue PoliciesAcupunctureMA12.004b1/1/20215/7/20215/7/2021Acupuncture
Reissue PoliciesScreening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA)MA09.013a2/18/20165/5/20215/7/2021Screening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA)
Reissue PoliciesPositron Emission Mammography (PEM)MA09.0151/1/20155/5/20215/7/2021Positron Emission Mammography (PEM)
Reissue PoliciesMoxetumomab pasudotox-tdfk (Lumoxiti™)MA08.103b10/1/20195/5/20215/7/2021Moxetumomab pasudotox-tdfk (Lumoxiti™)
Reissue PoliciesCerliponase alfa (Brineura®)MA08.089c6/3/20195/5/20215/10/20215/10/2021Cerliponase alfa (Brineura®)
Reissue PoliciesEmapalumab-lzsg (Gamifant®)MA08.104b10/1/20195/5/20215/10/20215/10/2021Emapalumab-lzsg (Gamifant®)
Reissue PoliciesCompression GarmentsMA05.045a5/6/20165/19/20215/21/2021Compression Garments
Reissue PoliciesNegative Pressure Wound Therapy (NPWT) SystemsMA05.008b8/17/20205/19/20215/21/2021Negative Pressure Wound Therapy (NPWT) Systems
Reissue PoliciesComposite Tissue Allotransplantation of the Hand(s) and FaceMA11.1125/21/20175/19/20215/21/2021Composite Tissue Allotransplantation of the Hand(s) and Face5/21/2021
Reissue PoliciesPercutaneous Intradiscal Annuloplasty (IDET/PIRFT)MA11.0251/1/20155/19/20215/21/2021Percutaneous Intradiscal Annuloplasty (IDET/PIRFT)
Reissue PoliciesComputer-Assisted Musculoskeletal Surgical Navigational Orthopedic ProcedureMA11.088c12/29/20205/19/20215/21/2021Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure
Reissue PoliciesPercutaneous Image-Guided Lumbar Decompression (PILD) for Spinal StenosisMA11.097d12/16/20195/19/20215/21/2021Percutaneous Image-Guided Lumbar Decompression (PILD) for Spinal Stenosis
Reissue PoliciesNon-Surgical Spinal Decompression TherapyMA11.021a3/28/20165/19/20215/21/2021Non-Surgical Spinal Decompression Therapy
Reissue PoliciesSpeech and Non-Speech Generating DevicesMA05.003d7/6/20205/19/20215/21/2021Speech and Non-Speech Generating Devices
Reissue PoliciesPulse Oximeters in the Home SettingMA05.042a5/7/20185/19/20215/21/2021Pulse Oximeters in the Home Setting
Reissue PoliciesCryosurgical Ablation of the Prostate GlandMA11.022a4/7/20155/19/20215/24/2021Cryosurgical Ablation of the Prostate Gland
Reissue PoliciesMogamulizumab-kpkc (Poteligeo®)MA08.102c1/18/20215/19/20215/24/2021Mogamulizumab-kpkc (Poteligeo®)
Reissue PoliciesLuspatercept–aamt (Reblozyl®)MA08.110b7/1/20205/19/20215/24/2021Luspatercept–aamt (Reblozyl®)
Reissue PoliciesDofetilide (Tikosyn®) Use in the Inpatient SettingMA08.021b9/22/20195/19/20215/24/2021Dofetilide (Tikosyn®) Use in the Inpatient Setting
Reissue PoliciesEdaravone (Radicava®)MA08.092a12/28/20185/19/20215/24/2021Edaravone (Radicava®)
Reissue PoliciesOcrelizumab (Ocrevus®)MA08.088c9/17/20195/19/20215/24/2021Ocrelizumab (Ocrevus®)
Reissue PoliciesSebelipase alfa (Kanuma®)MA08.078d6/18/20205/19/20215/24/2021Sebelipase alfa (Kanuma®)
Reissue PoliciesTagraxofusp-erzs (Elzonris®)MA08.105c5/23/20205/19/20215/24/2021Tagraxofusp-erzs (Elzonris®)
Reissue PoliciesEculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™)MA08.044f4/20/20205/19/20215/24/2021Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris™)
Reissue PoliciesComposite Tissue Allotransplantation of the Hand(s) and FaceMA11.1125/21/20175/19/20215/24/2021Composite Tissue Allotransplantation of the Hand(s) and Face